載入...
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of pharmacotherapeutics for type 2 diabetes management that work by reducing renal reabsorption of glucose. Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes. OBJECTIVE: Th...
Na minha lista:
| 發表在: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8286902/ https://ncbi.nlm.nih.gov/pubmed/34285473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S281602 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|